Gold(I) complexes with alkylated PTA (1,3,5-triaza-7-phosphaadamantane) phosphanes as anticancer metallodrugs

Synthesis of Gold(I) Derivatives Bearing Alkylated 1,3,5‐Triaza‐7‐phosphaadamantane as Selective Anticancer Metallodrugs

“…In addition, water solubility and a balanced correlation between lipo‐ and hydrophilicity, which improves biodistribution and cellular uptake, can be enhanced by the use of water‐soluble ligands attached to the metallic centre. In this regard, PTA (1,3,5‐triaza‐7‐phosphaadamantane) and its derivatives are the most widely employed ligands for improving the water solubility of metallic complexes . Some of these compounds have displayed promising anticancer activity against primary, , and metastatic tumours , …”

Copper(i) targeting in the Alzheimer's disease context: a first example using the biocompatible PTA ligand

“…PTA presents some advantages as its small cone angle, its resistance to oxidation compared to other phosphines, its solubility in water, its biocompatibility and low intrinsic toxicity. 13 Another important characteristic is that there are several positions through which the molecule can be modified by alkylation or arylation in the nitrogen atoms 14 among other examples. PTA and PTA derivatives coordination compounds have thus been studied for biomedical applications.…”

Lipid-based nanoparticles containing cationic derivatives of PTA (1,3,5-triaza-7-phosphaadamantane) as innovative vehicle for Pt complexes: Production, characterization and in vitro studies

“…Notably, the alkylation of one nitrogen of PTA leads to a group of derivatives bearing a positive charge while maintaining the coordinative ability through the P-donor site ( Fig. 1B) (García-Moreno et al, 2014;Wheate and Collins, 2003). When N-alkylated PTA derivatives are introduced as ligands in platinum or ruthenium complexes designed for anticancer activity, their cationic nature could be advantageous for the drug targeting.…”